TOKYO (dpa-AFX) - The U.S. Food and Drug Administration has acknowledged
Astellas Pharma's resubmission of the Biologics License Application (BLA) for
zolbetuximab, a first-in-class investigational claudin (CLDN) 18.2-targeted
monoclonal antibody, for the first-line treatment of adults with locally
advanced unresectable or metastatic human epidermal growth factor receptor 2
(HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose
tumors are CLDN18.2 positive, the company said in a statement.

If approved, zolbetuximab would be the first CLDN18.2-targeted therapy approved
for this patient population in the U.S. Under the Prescription Drug User Fee Act
(PDUFA), the FDA has set a new target action date of November 9, 2024.

The zolbetuximab BLA was resubmitted on May 9, 2024, following a complete
response letter issued on January 4, 2024 by the FDA due to third-party
manufacturing deficiencies identified during the pre-license inspection of the
facility. The FDA did not raise any concerns related to the clinical data,
including efficacy or safety, of zolbetuximab, and did not request additional
clinical studies to support the BLA approval.

For More Such Health News, visit rttnews.com.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX